Go to the list of all blogs
Anna G's Avatar
published in Blogs
Jun 01, 2023
TickeronGET DAILY SIGNALS
Incyte Corp (INCY, $62.58) Faces Downtrend: Analyzing Shareholder Returns and Economic Performance

Incyte Corp (INCY, $62.58) Faces Downtrend: Analyzing Shareholder Returns and Economic Performance

Are you ready to embrace the future of trading? Tickeron's AI robots empower investors to make smarter decisions.

 

Incyte Corp (INCY, $62.58) finds itself in the midst of a bearish trend, as indicated by A.I.dvisor's prediction of a potential Downtrend continuation. Shareholders have endured a challenging period, with a notable 38% decline in share price over the past three years and an additional 19% drop in the last quarter. To gain a comprehensive understanding of the company's current situation, it is essential to examine the correlation between shareholder returns and Incyte's underlying economics.

Over the past three years, while the broader market has returned approximately 40%, shareholders of Incyte have faced a contrasting experience with a significant decline of 38%. This divergence raises questions about the company's economic performance and its ability to generate returns for its shareholders.

Delving deeper into Incyte's economic performance, it becomes crucial to analyze whether the company's financials align with the disappointing shareholder returns. By scrutinizing key indicators, such as revenue growth, profitability, and efficiency, we can shed light on the underlying factors contributing to the company's stock performance.

Incyte Corp's economic performance has a critical role to play in determining its future prospects. By assessing the correlation between shareholder returns and the company's financial metrics, we can better understand whether there are any disparities or potential catalysts that may drive a turnaround. This analysis provides valuable insights for investors seeking to navigate the evolving landscape of Incyte Corp and make informed decisions regarding their investment strategy.

It is essential to approach Incyte Corp's current bearish trend with a comprehensive understanding of its underlying economics and the factors influencing its share price. By staying informed and aware of the correlation between shareholder returns and the company's financial performance, investors can make more informed decisions about their investment in Incyte and evaluate its future potential.

 

Related Ticker: INCY

INCY in upward trend: price may jump up because it broke its lower Bollinger Band on October 01, 2026

INCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 40 cases where INCY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 68%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INCY's RSI Oscillator exited the oversold zone, 21 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on INCY as a result. In 63 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.

The Moving Average Convergence Divergence (MACD) for INCY just turned positive on October 20, 2026. Looking at past instances where INCY's MACD turned positive, the stock continued to rise in 22 of 35 cases over the following month. The odds of a continued upward trend are 63%.

Following a +3.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in 207 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

INCY moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for INCY crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

The Aroon Indicator for INCY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 30 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 70 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.757) is normal, around the industry mean (3.051). P/E Ratio (14.464) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (10.822) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (4.401) is also within normal values, averaging (439.647).

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.2B. The market cap for tickers in the group ranges from 58 to 134.53B. VRTX holds the highest valuation in this group at 134.53B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -17%. INO experienced the highest price growth at 87%, while ABOS experienced the biggest fall at -90%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 4%. For the same stocks of the Industry, the average monthly volume growth was 9% and the average quarterly volume growth was -45%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 45
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
INCY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of drugs

Industry Biotechnology

Industry
Biotechnology
Address
1801 Augustine Cut-Off
Phone
+1 302 498-6700
Employees
2844
Web
https://www.incyte.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
Analysts expect Q1 2026 revenue of approximately $8.5 billion, a roughly 5% increase from $8.1 billion in Q1 2025. Consensus adjusted earnings per share (EPS) forecast stands at $4.74, reflecting a potential decline from prior-year levels amid pricing pressures.
Analysts expect Q1 2026 adjusted EPS of around $1.61, down from prior year levels due to softer commodity prices. Consensus revenue forecast stands at approximately $14.5 billion, reflecting a year-over-year decline.